IJMS | Free Full-Text | A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
Adalimumab for the treatment of fistulas in patients with Crohn's disease | Gut
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial - ScienceDirect
Adalimumab (CLASSIC & CHARM trial - Crohn) | Digestive Disease Dashboard
Long-term safety and effectiveness of adalimumab in 462 patients with intestinal Behçet's disease: results from a large real-world observational study
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
HUMIRA® (adalimumab) for Crohn's Disease in adults
Frontiers | Administration Timing Is the Best Clinical Outcome Predictor for Adalimumab Administration in Crohn's Disease
Adalimumab for Maintenance of Clinical Response and Remission in Patients With Crohn's Disease: The CHARM Trial
Effectiveness and safety of adalimumab biosimilar in inflammatory bowel disease: A multicenter study | SpringerLink
M02-404 (CSR)
Refining the Role of TNF Antagonists for Crohn's Disease
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study - The Lancet Gastroenterology & Hepatology
Design of the included studies of adalimumab for Crohn?s disease (CD).... | Download Scientific Diagram
Adalimumab (CLASSIC & CHARM trial - Crohn) | Digestive Disease Dashboard
Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE - Panaccione - 2013 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
Efficacy and effectiveness of biologic therapy in inflammatory bowel disease. EFIFECT study | Gastroenterología y Hepatología (English Edition)
Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis | European Journal of Medical Research | Full Text
Patients Enrolled in Randomized Controlled Trials Do Not Represent the Inflammatory Bowel Disease Patient Population - Clinical Gastroenterology and Hepatology
Refining the Role of TNF Antagonists for Crohn's Disease
IJMS | Free Full-Text | Tumor Necrosis Factor's Pathway in Crohn's Disease: Potential for Intervention
